EditorialPublished 2014
Approval for Novel Drugs in Chronic Lymphocytic Leukemia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Chronic lymphocytic leukemia (CLL) is a mature B-cell lymphoid neoplasm characterized by the proliferation and accumulation of small CD5/CD19/CD23-positive lymphocytes in the blood, lymph nodes, spleen, liver and bone marrow. It is the most prevalent leukemia in the western world with an estimated 15,720 new cases in 2014 and almost 4600 attributable deaths per year in the United States. CLL is typically sensitive to a variety of cytotoxic drugs, but the disease is considered incurable. Cytotoxic agents, including chlorambucil, bendamustin and purine analogs, currently constitute the basis of the most frequently used therapeutic regimens. In addition, anti- CD20 monoclonal antibodies (mAbs), rituximab and ofatumumab, and the anti-CD52 antibody alemtuzumab, alone or in combination with cytotoxic drugs, have been included for therapeutic options in this leukemia.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tadeusz Robak”
